Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

45.69
-1.3000-2.77%
Volume:884.71K
Turnover:40.74M
Market Cap:1.56B
PE:-7.06
High:47.13
Open:47.11
Low:45.50
Close:46.99
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:1.23
T/O Rate:3.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.73
PE(LYR):-4.70

Loading ...

B. Riley Securities Keeps Their Buy Rating on Nektar Therapeutics (NKTR)

TIPRANKS
·
2 hours ago

Nektar Therapeutics Price Target Maintained with a $185.00/Share by HC Wainwright & Co.

Dow Jones
·
3 hours ago

Nektar selloff yesterday overdone, says H.C. Wainwright

TIPRANKS
·
4 hours ago

Movement Alert|Nektar Therapeutics Falls 19.63% in Regular Trading, Trading at $48.81

Market Focus
·
20 hours ago

Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says Jefferies

TIPRANKS
·
20 hours ago

William Blair says rezpeg data a positive for Nektar

TIPRANKS
·
22 hours ago

Nektar Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since February 2023

Dow Jones
·
23 hours ago

Nektar falls -21.6%

TIPRANKS
·
23 hours ago

Nektar Stock Sinks Despite Promising Hair Loss Treatment Data

Dow Jones
·
Yesterday

Nektar Says Phase 3 Zenith AD Trial for Rezpegaldesleukin Expands into Treatment-Experienced Patients

Reuters
·
Yesterday

Nektar Therapeutics - Rezpegaldesleukin Demonstrates Durability and Deepening of Response Through One Year of Treatment

THOMSON REUTERS
·
Yesterday

Nektar Therapeutics - Rezpegaldesleukin Safety Profile Through 52 Weeks Favorable and Consistent with Previous Reports

THOMSON REUTERS
·
Yesterday

Nektar Therapeutics - Phase 3 Zenith Aa Study to Initiate in Early 2027

THOMSON REUTERS
·
Yesterday

Nektar Therapeutics - Salt Score ≤20 Response Maintained in 75% at 4 Months, 63% at 6 Months Off Treatment

THOMSON REUTERS
·
Yesterday

Nektar Therapeutics Says Rezpegaldesleukin in Atopic Dermatitis Showed Improvements as Early as Week 2

MT Newswires Live
·
Yesterday

Nektar: Rezpegaldesleukin-associated improvements detected as early as Week 2

TIPRANKS
·
Sep 30

Nektar Says Rezpegaldesleukin Shows Early Biomarker Response in Phase 2b Rezolve-AD Atopic Dermatitis Study

Reuters
·
Sep 30

Nektar Says Phase 2b Rezolve-AA Trial Posts New 6-Month Off-Treatment Rezpegaldesleukin Data in Severe Alopecia Areata

Reuters
·
Sep 28

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (Eadv) Congress 2026

THOMSON REUTERS
·
Sep 28

Canaccord Genuity Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 28